Medesis Pharma Shares Outstanding vs. Total Debt
| ALMDP Stock | EUR 0.35 0.01 2.94% |
For Medesis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medesis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medesis Pharma SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medesis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medesis Pharma SA over time as well as its relative position and ranking within its peers.
Medesis |
Medesis Pharma SA Total Debt vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Medesis Pharma's current stock value. Our valuation model uses many indicators to compare Medesis Pharma value to that of its competitors to determine the firm's financial worth. Medesis Pharma SA is number one stock in shares outstanding category among its peers. It also is the top company in total debt category among its peers making up about 0.29 of Total Debt per Shares Outstanding. The ratio of Shares Outstanding to Total Debt for Medesis Pharma SA is roughly 3.42 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medesis Pharma's earnings, one of the primary drivers of an investment's value.Medesis Total Debt vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Medesis Pharma |
| = | 4.39 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Medesis Pharma |
| = | 1.28 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Medesis Total Debt vs Competition
Medesis Pharma SA is the top company in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 103.71 Million. Medesis Pharma claims roughly 1.28 Million in total debt contributing just under 2% to stocks in Biotechnology industry.
Medesis Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Medesis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medesis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Medesis Pharma's change in net profit over the period of time. It can combine multiple indicators of Medesis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. The company was founded in 2003 and is based in Montpellier, France. MEDESIS PHARMA is traded on Paris Stock Exchange in France.
Medesis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Medesis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medesis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medesis Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Medesis Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Medesis Pharma position
In addition to having Medesis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Online Gaming Thematic Idea Now
Online Gaming
Companies that are involved in the building and marketing of online gaming-related products. The Online Gaming theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Online Gaming Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.